Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.

Martin M, Hegg R, Kim SB, Schenker M, Grecea D, Garcia-Saenz JA, Papazisis K, Ouyang Q, Lacko A, Oksuzoglu B, Reeves J, Okera M, Testa L, Shimizu C, Denduluri N, Adamchuk H, Dakhil S, Wei R, Forrester T, Fernandez MM, Zimmermann A, Headley D, Johnston SRD.

Open source

DOI: 10.1001/jamaoncol.2022.1488
Published: 2022-08-01
Container: JAMA Oncol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2022.1488,
  title = {Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.},
  author = {Martin M and  Hegg R and  Kim SB and  Schenker M and  Grecea D and  Garcia-Saenz JA and  Papazisis K and  Ouyang Q and  Lacko A and  Oksuzoglu B and  Reeves J and  Okera M and  Testa L and  Shimizu C and  Denduluri N and  Adamchuk H and  Dakhil S and  Wei R and  Forrester T and  Fernandez MM and  Zimmermann A and  Headley D and  Johnston SRD.},
  year = {2022},
  journal = {JAMA Oncol},
  doi = {10.1001/jamaoncol.2022.1488},
  url = {https://doi.org/10.1001/jamaoncol.2022.1488}
}

RIS

TY  - JOUR
TI  - Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
AU  - Martin M
AU  -  Hegg R
AU  -  Kim SB
AU  -  Schenker M
AU  -  Grecea D
AU  -  Garcia-Saenz JA
AU  -  Papazisis K
AU  -  Ouyang Q
AU  -  Lacko A
AU  -  Oksuzoglu B
AU  -  Reeves J
AU  -  Okera M
AU  -  Testa L
AU  -  Shimizu C
AU  -  Denduluri N
AU  -  Adamchuk H
AU  -  Dakhil S
AU  -  Wei R
AU  -  Forrester T
AU  -  Fernandez MM
AU  -  Zimmermann A
AU  -  Headley D
AU  -  Johnston SRD.
PY  - 2022
JO  - JAMA Oncol
DO  - 10.1001/jamaoncol.2022.1488
UR  - https://doi.org/10.1001/jamaoncol.2022.1488
ER  -

APA

M, M., R, H., SB, K., M, S., D, G., JA, G., K, P., Q, O., A, L., B, O., J, R., M, O., L, T., C, S., N, D., H, A., S, D., R, W., T, F., MM, F., A, Z., D, H., & SRD., J. (2022). Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2022.1488

Source records

europe-pmc · retrieved 2026-09-26T22:39:58.221Z